Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) bevacizurnab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Wardley, A.
Lohrisch, C.
Joy, A. A.
Young, S.
Yi, F. F.
Marme, A.
Dreosti, L.
Albanell, J.
Munoz, M.
Miles, D. W.
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Hop Reg Sudbury Reg Hosp, Sudbury, ON, Canada
[5] Peking Union Med Coll, Beijing 100021, Peoples R China
[6] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[7] Univ Tubingen, Tubingen, Germany
[8] Univ Pretoria, ZA-0002 Pretoria, South Africa
[9] Hosp del Mar, Barcelona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Vernon Canc Ctr, Middlesex, England
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116S / 116S
页数：1
相关论文
共 50 条
  • [1] Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizurnab (BV) or placebo (PL) in the AVADO phase III study
    Cortes, J.
    Pivot, X.
    Schneeweiss, A.
    Wilcken, N.
    Ellis, P.
    Linderholm, B. K.
    Ribelles, N.
    Clemens, M.
    Haslbauer, F.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 115S - 115S
  • [2] Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study
    Dirix, L. Y.
    Romieu, G.
    Provencher, L.
    Grimes, D.
    de Souzo, Viana L.
    Paterson, A.
    Mauriac, L.
    Kirsch, A.
    Pernas, S.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 285S - 285S
  • [3] Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study
    Pivot, X.
    Verma, S.
    Thomssen, C.
    Passos-Coelho, J. L.
    Latini, L.
    Ciruelos, E.
    Silva, M.
    von Moos, R.
    Chang, H.
    Miles, D. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] QUALITY OF LIFE (QOL) AMONG PATIENTS (PTS) WITH LOCALLY RECURRENT (LR) OR METASTATIC BREAST CANCER (MBC): RESULTS FROM THE PHASE III AVADO STUDY OF FIRST-LINE BEVACIZUMAB (BV) PLUS DOCETAXEL (D) VERSUS D PLUS PLACEBO (PL)
    Greil, R.
    Im, Y. H.
    Pienkowski, T.
    Wardley, A.
    Awada, A.
    Ciruelos, E.
    Freitas-Junior, R.
    Fumoleau, P.
    Sriuranpong, V.
    Miles, D. W.
    ANNALS OF ONCOLOGY, 2008, 19 : 67 - 67
  • [5] Evidence from the phase III AVADO study reveals no increase in tumour malignant potential following treatment of metastatic breast cancer (mBC) with bevacizumab (BV) and docetaxel (D)
    Chan, A.
    Miles, D. W.
    ten Bokkel Huinink, D.
    Durando, X.
    Fabiani, C.
    Salvagni, S.
    Perez-Michel, L.
    Schneeweise, A.
    Harbeck, N.
    EJC SUPPLEMENTS, 2010, 8 (03): : 199 - 200
  • [6] No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study.
    Harbeck, N.
    Chan, A.
    Huinink, D. ten Bokkel
    Chollet, P.
    Gimenes, D. L.
    Fabiani, C.
    Salvagni, S.
    Perez-Michel, L.
    Schneeweiss, A.
    Chlistalla, A.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (24) : 852S - 852S
  • [7] Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVAIDO phase III study
    Chan, A.
    Vanlemmens, L.
    Conte, P. F.
    Beith, J.
    Samonigg, H.
    Verma, S.
    Srimuninnimit, V
    Martoni, A.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 114S - 114S
  • [8] Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally recurrent (LR) or metastatic breast cancer (mBC)
    Greil, R.
    Im, Y. H.
    Pienkowski, T.
    Wardley, A.
    Awada, A.
    Ciruelos, E.
    Freitas-Junior, R.
    Fumoleau, P.
    Miles, D. W.
    EJC SUPPLEMENTS, 2009, 7 (02): : 266 - 266
  • [9] Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC)
    Miles, D. W.
    Chan, A.
    Romieu, G.
    Dirix, L.
    Cortes, J.
    Pivot, X.
    Tomczak, P.
    Juozaityte, E.
    Harbeck, N.
    Steger, G. G.
    CANCER RESEARCH, 2009, 69 (24) : 495S - 495S
  • [10] Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV plus docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC])
    Fumoleau, P.
    Greil, R.
    Rayson, D.
    Mueller, V
    Barni, S.
    Aleknavicius, E.
    Tellez, E.
    Wilson, C.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 104S - 104S
12345